Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195468
Status:
COMPLETED
Last Update Posted:
2011-03-08
First Post:
2005-09-13
Brief Title:
Study Comparing Cyclosporine Dose Reduction vs Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Randomized Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Compare kidney function as measured by calculated creatinine clearance using the method by Nankivell1 at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion CsA and Rapamune followed by CsA dose reduction Group I with subjects receiving induction therapy with CsA and Rapamune followed by CsA discontinuation Group II
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None